GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Cash Flow from Financing

Celadon Pharmaceuticals (LSE:CEL) Cash Flow from Financing : €2.91 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Celadon Pharmaceuticals paid €0.00 Mil more to buy back shares than it received from issuing new shares. It received €0.01 Mil from issuing more debt. It paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received €0.00 Mil from paying cash dividends to shareholders. It received €3.47 Mil on other financial activities. In all, Celadon Pharmaceuticals earned €3.48 Mil on financial activities for the six months ended in Dec. 2023.


Celadon Pharmaceuticals Cash Flow from Financing Historical Data

The historical data trend for Celadon Pharmaceuticals's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Cash Flow from Financing Chart

Celadon Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
- 1.19 9.31 6.84 2.92

Celadon Pharmaceuticals Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial 4.38 6.93 - -0.29 3.20

Celadon Pharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Celadon Pharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Celadon Pharmaceuticals's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celadon Pharmaceuticals  (LSE:CEL) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Celadon Pharmaceuticals's issuance of stock for the six months ended in Dec. 2023 was €0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Celadon Pharmaceuticals's repurchase of stock for the six months ended in Dec. 2023 was €0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Celadon Pharmaceuticals's net issuance of debt for the six months ended in Dec. 2023 was €0.01 Mil. Celadon Pharmaceuticals received €0.01 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Celadon Pharmaceuticals's net issuance of preferred for the six months ended in Dec. 2023 was €0.00 Mil. Celadon Pharmaceuticals paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Celadon Pharmaceuticals's cash flow for dividends for the six months ended in Dec. 2023 was €0.00 Mil. Celadon Pharmaceuticals received €0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Celadon Pharmaceuticals's other financing for the six months ended in Dec. 2023 was €3.47 Mil. Celadon Pharmaceuticals received €3.47 Mil on other financial activities.


Celadon Pharmaceuticals Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Celadon Pharmaceuticals (LSE:CEL) Business Description

Traded in Other Exchanges
N/A
Address
32-33 Cowcross Street, London, GBR, EC1M 6DF
Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines